---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-066145"
form_type: "8-K"
ticker: "ADTX"
cik: "0001726711"
company_name: "Aditxt, Inc."
filed_at: "2025-07-21T23:59:59+00:00"
generated_at: "2026-05-18T05:11:47.200334+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Aditxt subsidiary Pearsanta targets prostate cancer test launch by end-2025; IPO spin-off planned

## Summary
- Pearsanta plans to launch a lab-developed test for prostate cancer using mitochondrial DNA detection by end of 2025.
- CEO Amro Albanna stated 70% of cancer deaths could be prevented if caught early; Pearsanta aims for early detection via non-invasive blood test.
- Aditxt plans to spin off Pearsanta via IPO, retaining ~60% ownership; values Aditxt's stake potentially at $60M vs. current $5M market cap.
- The test will initially run at CLIA/CAP lab in Richmond, VA; FDA submission for kit development planned later.
- Other subsidiaries highlighted: Adimune (autoimmunity) and pending Adifem/Evofem acquisition (women's health) expected to close by September 2025.

## SEC filing metadata
- accession: 0001213900-25-066145
- form_type: 8-K
- ticker: ADTX
- cik: 0001726711
- company_name: Aditxt, Inc.
- filed_at: 2025-07-21T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726711/000121390025066145/0001213900-25-066145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726711/000121390025066145/ea0249677-8k_aditxt.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-066145
- JSON: https://secwatch.observer/filing/0001213900-25-066145.json
- Plain text: https://secwatch.observer/filing/0001213900-25-066145.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.